Raymond James Downgrades GoodRx Holdings Inc. (GDRX) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St futures gain as AI, consulting stocks offset bond-market jitters
- Oil prices rise 2% as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- These 5 AI chip stocks are must-own into Q4, BofA says
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
GoodRx Holdings Inc. (GDRX) PT Lowered to $12 at Goldman Sachs
May 10, 2022 7:00 AM EDTGoldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $12.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "In its Q1 22 earnings report, GoodRx presented a solid quarterly report but framed the forward business trajectory as impacted by a "grocer" partner that had... More
